Jiangsu Alphamab Biopharmaceuticals Co., Ltd

This study tests a new drug called JSKN016 against standard treatments for people with advanced triple-negative breast cancer that has not responded to at least two prior therapies. The goal is to see if JSKN016 can slow cancer growth or extend survival. About 364 adults aged 18 …

This early-stage study tests a new drug combination (JSKN016 plus other treatments) in 288 people with advanced non-small cell lung cancer that has spread and cannot be removed by surgery. The main goals are to see if the treatment shrinks tumors and to check for side effects. Th…

This early-stage trial is testing a new drug called JSKN022 in 225 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check the drug's safety and find the best dose. Researchers will also look for early signs that the drug might …

This study tests a new drug called JSKN016, given with chemotherapy or immunotherapy, for people with HER2-negative breast cancer that cannot be removed by surgery or has spread. The trial includes 180 adults in China and aims to see if the combination shrinks tumors and how safe…

This study tests a new drug called JSKN003 against standard chemotherapy in 400 people with HER2-low breast cancer that has spread and stopped responding to earlier treatments. Participants are randomly assigned to receive either JSKN003 or a standard chemo drug chosen by their d…